ATE512674T1 - Angiopep-1, verwandte verbindungen, und deren verwnedungen - Google Patents
Angiopep-1, verwandte verbindungen, und deren verwnedungenInfo
- Publication number
- ATE512674T1 ATE512674T1 AT04700102T AT04700102T ATE512674T1 AT E512674 T1 ATE512674 T1 AT E512674T1 AT 04700102 T AT04700102 T AT 04700102T AT 04700102 T AT04700102 T AT 04700102T AT E512674 T1 ATE512674 T1 AT E512674T1
- Authority
- AT
- Austria
- Prior art keywords
- blood
- brain barrier
- carrier
- relates
- agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43798603P | 2003-01-06 | 2003-01-06 | |
| PCT/CA2004/000011 WO2004060403A2 (en) | 2003-01-06 | 2004-01-05 | Aprotinin and anglos as carriers across the blood-brain barrier |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE512674T1 true ATE512674T1 (de) | 2011-07-15 |
Family
ID=32713262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04700102T ATE512674T1 (de) | 2003-01-06 | 2004-01-05 | Angiopep-1, verwandte verbindungen, und deren verwnedungen |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9221867B2 (de) |
| EP (2) | EP2260874A1 (de) |
| JP (2) | JP4903036B2 (de) |
| CN (2) | CN102775472A (de) |
| AT (1) | ATE512674T1 (de) |
| AU (2) | AU2004203682B2 (de) |
| BR (1) | BRPI0406647A (de) |
| CA (1) | CA2516056C (de) |
| CY (1) | CY1111844T1 (de) |
| DK (1) | DK1583562T3 (de) |
| ES (1) | ES2368941T3 (de) |
| MX (1) | MXPA05007322A (de) |
| PT (1) | PT1583562E (de) |
| SI (1) | SI1583562T1 (de) |
| WO (1) | WO2004060403A2 (de) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004060403A2 (en) * | 2003-01-06 | 2004-07-22 | Angiochem Inc. | Aprotinin and anglos as carriers across the blood-brain barrier |
| US7906625B2 (en) * | 2005-01-24 | 2011-03-15 | Amgen Inc. | Humanized anti-amyloid antibody |
| RU2408605C2 (ru) * | 2005-02-18 | 2011-01-10 | Анджиокем Инк. | Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат |
| US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| ES2744225T3 (es) | 2005-07-15 | 2020-02-24 | Angiochem Inc | Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos |
| EP1985311A4 (de) * | 2006-01-24 | 2011-04-13 | Univ Kagoshima | Agens zur zielsteuerung eines arzneistoffs auf zerebrale neuronen |
| US20090239942A1 (en) * | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
| JP2010506860A (ja) | 2006-10-19 | 2010-03-04 | アンジオケム，インコーポレーテッド | Ｐ−糖タンパク質機能を刺激するための化合物およびその使用 |
| US9365634B2 (en) * | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| PT2164866E (pt) * | 2007-05-29 | 2014-08-04 | Angiochem Inc | Polipéptidos de tipo aprotinina para administrar agentes conjugados com os mesmos aos tecidos |
| AU2008255556B2 (en) * | 2007-05-29 | 2014-08-07 | Angiochem, Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| EP2235058A2 (de) | 2007-12-21 | 2010-10-06 | Amgen, Inc | Anti-amyloid-antikörper und ihre verwendung |
| MX355683B (es) * | 2008-04-18 | 2018-04-26 | Angiochem Inc | Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso. |
| US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
| US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
| US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
| US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
| US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
| US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
| US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
| US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
| US10245098B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Acute blood-brain barrier disruption using electrical energy based therapy |
| US9598691B2 (en) | 2008-04-29 | 2017-03-21 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
| US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
| US8992517B2 (en) | 2008-04-29 | 2015-03-31 | Virginia Tech Intellectual Properties Inc. | Irreversible electroporation to treat aberrant cell masses |
| CA2740316A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| WO2010043049A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
| CA2745524C (en) | 2008-12-05 | 2020-06-09 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| US8853353B2 (en) | 2008-12-17 | 2014-10-07 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| DE102009006228A1 (de) | 2009-01-27 | 2010-07-29 | Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh | Liposomale Zusammensetzung zur Behandlung von Hirnmetastasen |
| US8632534B2 (en) | 2009-04-03 | 2014-01-21 | Angiodynamics, Inc. | Irreversible electroporation (IRE) for congestive obstructive pulmonary disease (COPD) |
| US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
| US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
| MX2011011023A (es) | 2009-04-20 | 2012-01-20 | Angiochem Inc | Tratamiento de cancer de ovarios usando un agente anti-cancer conjugado con un analogo de angiopep-2. |
| WO2010138919A2 (en) | 2009-05-28 | 2010-12-02 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
| US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
| RU2012103240A (ru) * | 2009-07-02 | 2013-08-10 | Ангиокем Инк. | Мультимерные пептидные конъюгаты и их применение |
| JP5548695B2 (ja) * | 2009-10-30 | 2014-07-16 | 学校法人慶應義塾 | 抗がん剤の感受性判定マーカー |
| JP2013530993A (ja) * | 2010-07-02 | 2013-08-01 | アンジオケム インコーポレーテッド | 治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用 |
| EP2627274B1 (de) | 2010-10-13 | 2022-12-14 | AngioDynamics, Inc. | System zur elektrischen ableitung des gewebes eines patienten |
| WO2012088149A2 (en) | 2010-12-20 | 2012-06-28 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
| KR20140026372A (ko) | 2011-02-02 | 2014-03-05 | 이무노퓨처 아이앤씨. | 혈액-뇌 장벽을 투과하는 약물 전달체, 펩티드 및 이의 용도 |
| US9078665B2 (en) | 2011-09-28 | 2015-07-14 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
| US9414881B2 (en) | 2012-02-08 | 2016-08-16 | Angiodynamics, Inc. | System and method for increasing a target zone for electrical ablation |
| JP2015526434A (ja) | 2012-08-14 | 2015-09-10 | アンジオケム インコーポレーテッド | ペプチド−デンドリマーコンジュゲート及びその使用 |
| US9888956B2 (en) | 2013-01-22 | 2018-02-13 | Angiodynamics, Inc. | Integrated pump and generator device and method of use |
| AU2014243816B2 (en) * | 2013-03-13 | 2019-01-31 | Bioasis Technologies Inc. | Fragments of p97 and uses thereof |
| US20150093399A1 (en) | 2013-08-28 | 2015-04-02 | Bioasis Technologies, Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| PT3052485T (pt) | 2013-10-04 | 2021-10-22 | Infinity Pharmaceuticals Inc | Compostos heterocíclicos e suas utilizações |
| MX382033B (es) | 2014-03-19 | 2025-03-13 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. |
| AU2015259303B2 (en) | 2014-05-12 | 2021-10-28 | Arena, Christopher B. | Selective modulation of intracellular effects of cells using pulsed electric fields |
| US12114911B2 (en) | 2014-08-28 | 2024-10-15 | Angiodynamics, Inc. | System and method for ablating a tissue site by electroporation with real-time pulse monitoring |
| WO2016061801A1 (zh) * | 2014-10-24 | 2016-04-28 | 中国科学技术大学 | 用于淀粉样蛋白显像的血管肽及其衍生物 |
| CN105585614B (zh) * | 2014-10-24 | 2019-06-07 | 中国科学技术大学 | 用于淀粉样蛋白显像的血管肽及其衍生物 |
| US10694972B2 (en) | 2014-12-15 | 2020-06-30 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
| EP3307326B9 (de) | 2015-06-15 | 2021-02-24 | Angiochem Inc. | Verfahren zur behandlung von leptomeningealer karzinomatose |
| US11207461B2 (en) | 2015-07-30 | 2021-12-28 | Anoop U. R | Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier |
| WO2017048702A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| CN106188308B (zh) * | 2016-07-12 | 2019-08-20 | 西安医学院 | 一种跨血脑屏障蛋白转运体及制备方法和应用 |
| US10905492B2 (en) | 2016-11-17 | 2021-02-02 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
| EP3634978A1 (de) | 2017-06-07 | 2020-04-15 | Adrx, Inc. | Tau-aggregationshemmer |
| EP3668886A2 (de) | 2017-08-18 | 2020-06-24 | Adrx, Inc. | Peptidinhibitoren der tau-aggregation |
| US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
| US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
| US12419832B2 (en) | 2018-01-29 | 2025-09-23 | Cognos Therapeutics, Inc. | Intratumoral delivery of bortezomib |
| US12390262B2 (en) | 2018-03-13 | 2025-08-19 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
| US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
| US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
| US10842755B2 (en) | 2018-03-23 | 2020-11-24 | University Of South Carolina | Nanoparticles for brain targeted drug delivery |
| US11950835B2 (en) | 2019-06-28 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
| US12214189B2 (en) | 2019-07-24 | 2025-02-04 | Virginia Tech Intellectual Properties, Inc. | Fourier analysis spectroscopy for monitoring tissue impedance changes and treatment outcome during electroporation-based-therapies |
| CA3128035A1 (en) | 2020-08-13 | 2022-02-13 | Bioasis Technologies, Inc. | Combination therapies for delivery across the blood brain barrier |
| US12485279B2 (en) | 2020-11-25 | 2025-12-02 | Virginia Tech Intellectual Properties, Inc. | Methods for modulating temporal infrastructure of pulsed electric fields |
Family Cites Families (184)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| AU599373B2 (en) | 1986-03-13 | 1990-07-19 | Biotechnology Australia Proprietary Limited | Method of assay of inhibin |
| US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4904768A (en) | 1987-08-04 | 1990-02-27 | Bristol-Myers Company | Epipodophyllotoxin glucoside 4'-phosphate derivatives |
| GB2208511A (en) | 1987-08-07 | 1989-04-05 | Bayer Ag | Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology |
| US4942184A (en) | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
| US5632990A (en) | 1988-04-22 | 1997-05-27 | Cancer Research Campaign Tech. Ltd. | Treatment for tumors comprising conjugated antibody A5B7 and a prodrug |
| US5258499A (en) | 1988-05-16 | 1993-11-02 | Vestar, Inc. | Liposome targeting using receptor specific ligands |
| US5028697A (en) | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
| US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5948634A (en) | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
| DE3912638A1 (de) | 1989-04-18 | 1990-10-31 | Bayer Ag | Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel |
| US5126249A (en) | 1989-05-09 | 1992-06-30 | Eli Lilly And Company | Enzymatic removal of a protein amino-terminal sequence |
| US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| US6475781B1 (en) | 1990-05-17 | 2002-11-05 | Dana-Farber Cancer Institute, Inc. | Trans-dominant suppressor genes for oligomeric proteins |
| GB9017008D0 (en) | 1990-08-02 | 1990-09-19 | Erba Carlo Spa | Process for the enzymatic preparation of basic fibroblast growth factor |
| US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
| JPH07108232B2 (ja) * | 1990-10-09 | 1995-11-22 | エム・ディ・リサーチ株式会社 | ペプチド又は蛋白質の製造方法 |
| US6495513B1 (en) | 1991-03-11 | 2002-12-17 | Curis, Inc. | Morphogen-enhanced survival and repair of neural cells |
| US5955444A (en) | 1991-08-09 | 1999-09-21 | Massachusetts Institute Of Technology | Method of inhibiting abnormal tau hyper phosphorylation in a cell |
| US5627270A (en) | 1991-12-13 | 1997-05-06 | Trustees Of Princeton University | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
| US5204354A (en) | 1992-02-14 | 1993-04-20 | Merck & Co., Inc. | Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders |
| GB9213077D0 (en) | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
| EP0671944A4 (de) | 1992-09-25 | 1996-07-24 | Corvas Int Inc | Inhibitoren des faktor viia-gewebsfaktorrkomplex abegeleitet vom pankreatischerinder-trypsininhibitor. |
| EP0599303A3 (de) | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide-Konjugate |
| WO1994019692A1 (en) | 1993-02-18 | 1994-09-01 | The General Hospital Corporation | Alzheimer's disease therapeutics |
| EP0820466A2 (de) | 1995-04-04 | 1998-01-28 | Advanced Bioconcept Inc. | Fluoreszierende peptide |
| ZA963619B (en) | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
| KR19990008458A (ko) | 1995-05-08 | 1999-01-25 | 쉬어러 피터 알. | 쿠니츠(kunitz) 타입 프로테아제 억제 물질 |
| WO1996039183A1 (en) | 1995-05-31 | 1996-12-12 | Fred Hutchinson Cancer Research Center | Compositions and methods for targeted delivery of effector molecules |
| US5780265A (en) | 1995-06-05 | 1998-07-14 | Genentech, Inc. | Kunitz type plasma kallikrein inhibitors |
| US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| JP3469584B2 (ja) | 1996-03-11 | 2003-11-25 | バイエル コーポレイション | ヒト ビクニン |
| AU2409397A (en) | 1996-04-24 | 1997-11-12 | Rijksuniversiteit Te Groningen | A prokaryotic protein having functional and structural homology with the uman p-glycoprotein encoded by the mdr-1 gene, nucleic acids encoding and cells expressing said protein |
| AU729643B2 (en) | 1996-05-01 | 2001-02-08 | Antivirals Inc. | Polypeptide conjugates for transporting substances across cell membranes |
| DE19636889A1 (de) | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
| JP2001503396A (ja) | 1996-10-11 | 2001-03-13 | アルザ コーポレイション | 治療用リポソーム組成物および方法 |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US5948750A (en) | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| AU6682598A (en) | 1997-03-04 | 1998-09-22 | Bio-Technology General Corporation | Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs |
| GB9705903D0 (en) | 1997-03-21 | 1997-05-07 | Elliott Gillian D | VP22 Proteins and uses thereof |
| US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
| CN1263473A (zh) | 1997-05-21 | 2000-08-16 | 利兰·斯坦福青年大学托管委员会 | 增加跨生物膜转运的组合物和方法 |
| US6391305B1 (en) | 1997-09-10 | 2002-05-21 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| US6093692A (en) | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
| US6475481B2 (en) | 1997-11-18 | 2002-11-05 | Canji Inc | Purging of stem cell products |
| WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
| DE69933785T2 (de) | 1998-03-12 | 2007-10-04 | Georgetown University | Peptide enthaltend eine cholesterin-erkennungssequenz und deren verwendungen |
| US5981564A (en) | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
| GB9814527D0 (en) | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
| US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| US5922754A (en) | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
| MXPA01008699A (es) | 1999-02-24 | 2002-06-21 | Uab Research Foundation | Derivados de taxano para terapia de cancer dirigida. . |
| US6138375A (en) * | 1999-03-01 | 2000-10-31 | Gala Industries, Inc. | Support ring for pellet dryer screen |
| US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| ES2288871T3 (es) | 1999-09-24 | 2008-02-01 | Genentech, Inc. | Derivados de tirosina. |
| US6136846A (en) | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
| DE19953696A1 (de) * | 1999-11-09 | 2001-05-10 | Alexander Cherkasky | Selektive proteolytische Synzyme (SPS) |
| DE19953966A1 (de) * | 1999-11-09 | 2001-05-10 | Leica Microsystems | Verfahren und Vorrichtung zur Dickenmessung an transparenten Schichten |
| GB2360453B (en) | 2000-01-05 | 2004-09-01 | Univ Cardiff | Treatment of skin conditions |
| US20020086384A1 (en) | 2000-03-14 | 2002-07-04 | Zurit Levine | Splice variants of oncogenes |
| CA2355334A1 (en) | 2000-10-16 | 2002-04-16 | Procyon Biopharma Inc. | Pharmaceutical preparations and methods for inhibiting tumors |
| ES2284711T3 (es) | 2000-10-20 | 2007-11-16 | Abbott Laboratories | Tiagabina para el tratamiento de neuropatia diabetica. |
| US6919370B2 (en) | 2000-11-28 | 2005-07-19 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
| CA2441484A1 (en) | 2001-03-23 | 2002-10-03 | Napro Biotherapeutics, Inc. | Molecular conjugates for use in treatment of cancer |
| WO2002085923A2 (en) | 2001-04-19 | 2002-10-31 | The Scripps Research Institute | In vivo incorporation of unnatural amino acids |
| AU2002322720B2 (en) * | 2001-07-25 | 2008-11-13 | Raptor Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US20040161776A1 (en) | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
| US7192921B2 (en) | 2001-11-08 | 2007-03-20 | The Burnham Institute | Peptides that home to tumor lymphatic vasculature and methods of using same |
| AU2003209577A1 (en) | 2002-02-07 | 2003-09-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Amino acid sequences capable of facilitating penetration across a biological barrier |
| WO2003097671A1 (en) | 2002-03-29 | 2003-11-27 | Creagene Inc. | Cytoplasmic transduction peptides and uses thereof |
| US6881829B2 (en) | 2002-04-26 | 2005-04-19 | Chimeracom, L.L.C. | Chimeric hybrid analgesics |
| EP1514106A4 (de) | 2002-05-29 | 2007-05-09 | Zystor Therapeutics Inc | Gezielte therapeutische proteine |
| JP2005537244A (ja) | 2002-06-28 | 2005-12-08 | ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド | 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法 |
| US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
| US20040102369A1 (en) | 2002-11-27 | 2004-05-27 | The Regents Of The University Of California | Transport of basic fibroblast growth factor across the blood brain barrier |
| US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| US7319090B2 (en) | 2002-11-27 | 2008-01-15 | University Of North Carolina At Chapel Hill | Methods of treating cerebral ischemia |
| WO2004060403A2 (en) * | 2003-01-06 | 2004-07-22 | Angiochem Inc. | Aprotinin and anglos as carriers across the blood-brain barrier |
| US20040162284A1 (en) | 2003-02-19 | 2004-08-19 | Harris Herbert W. | Method of lowering body temperature with (S) tofisopam |
| NZ542791A (en) | 2003-04-08 | 2008-04-30 | Biotempt Bv | Compositions for mucosal and oral administration comprising HCG fragments |
| ATE508139T1 (de) | 2003-04-11 | 2011-05-15 | Pasteur Institut | Synthetische peptid-hiv-vakzine: das cbd-epitop als effizientes immunogen zur induktion hiv- neutralisierender antikörper |
| AU2003286870A1 (en) | 2003-06-05 | 2005-01-04 | Salk Institute For Biological Studies | Targeting polypeptides to the central nervous system |
| EP1638605B1 (de) | 2003-06-20 | 2014-01-08 | Raptor Pharmaceutical, Inc. | Abgabe von therapeutischen verbindungen an das gehirn und andere gewebe |
| US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| KR20060036476A (ko) | 2003-08-08 | 2006-04-28 | 가부시키가이샤 티슈 타겟팅 쟈판 | 뇌 이동 활성을 가지는 폴리펩티드 및 그 이용 |
| EP1663278A4 (de) | 2003-08-28 | 2009-07-29 | Biorexis Pharmaceutical Corp | Epo mimetika-peptide und fusionsproteine |
| US20050058702A1 (en) | 2003-09-17 | 2005-03-17 | Ben-Sasson Shmuel A. | Compositions capable of facilitating penetration across a biological barrier |
| US20050208095A1 (en) | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
| US7208174B2 (en) | 2003-12-18 | 2007-04-24 | Hoffmann-La Roche Inc. | Liposome compositions |
| WO2006091231A2 (en) | 2004-07-21 | 2006-08-31 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| CA2580189C (en) | 2004-09-29 | 2013-05-21 | Children's Memorial Hospital | Sirna-mediated gene silencing of alpha synuclein |
| US9002652B1 (en) | 2005-01-27 | 2015-04-07 | Institute For Systems Biology | Methods for identifying and using organ-specific proteins in blood |
| RU2408605C2 (ru) | 2005-02-18 | 2011-01-10 | Анджиокем Инк. | Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат |
| US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| KR20070114753A (ko) | 2005-02-18 | 2007-12-04 | 아브락시스 바이오사이언스 인크. | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| EP1877099B1 (de) | 2005-04-06 | 2012-09-19 | Genzyme Corporation | Therapeutische konjugate beinhaltend ein lysosomales enzym, polysialinsäure und eine zielkomponente |
| EP1888121A2 (de) | 2005-05-12 | 2008-02-20 | Tapestry Pharmaceuticals, Inc. | Gegen krebs gerichtete konjugate mit einem succinyl- oder glutaryl-linker |
| US8877714B2 (en) | 2005-06-14 | 2014-11-04 | Raptor Pharmaceutical Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof |
| ES2744225T3 (es) | 2005-07-15 | 2020-02-24 | Angiochem Inc | Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos |
| CA2615617A1 (en) | 2005-07-19 | 2007-01-25 | The Board Of Trustees Of The University Of Illinois | Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof |
| GB0517092D0 (en) | 2005-08-19 | 2005-09-28 | Novartis Ag | New compositions containing taxane derivatives |
| JP2009507852A (ja) | 2005-09-08 | 2009-02-26 | エムディーアールエヌエー，インコーポレイテッド | リボ核酸の細胞への送達用医薬組成物 |
| EP1945240B1 (de) | 2005-09-16 | 2016-12-28 | Raptor Pharmaceutical Inc | Zusammensetzungen mit rezeptor-assoziierten protein (rap) varianten, die für cr-haltige proteine spezifisch sind und ihre verwendungen |
| US8053569B2 (en) | 2005-10-07 | 2011-11-08 | Armagen Technologies, Inc. | Nucleic acids encoding and methods of producing fusion proteins |
| WO2007053696A2 (en) | 2005-11-01 | 2007-05-10 | Alnylam Pharmaceuticals, Inc. | Rnai inhibition of influenza virus replication |
| US8039432B2 (en) | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
| US8290433B2 (en) | 2007-11-14 | 2012-10-16 | Blaze Mobile, Inc. | Method and system for securing transactions made through a mobile communication device |
| AR054215A1 (es) | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| AU2007223855B2 (en) | 2006-03-06 | 2013-05-16 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
| US7477504B1 (en) | 2006-03-13 | 2009-01-13 | C.P.D. Technologies, Inc. | Versatile stun glove |
| JP5103466B2 (ja) | 2006-03-30 | 2012-12-19 | グラクソ グループ リミテッド | アミロイド‐βペプチドに対する抗体 |
| EP2043696B1 (de) | 2006-07-13 | 2015-02-25 | Burnham Institute for Medical Research | Verfahren und zusammensetzungen zum gc1qr/p32-targeting |
| CN101511868B (zh) | 2006-07-24 | 2013-03-06 | 比奥雷克西斯制药公司 | 毒蜥外泌肽融合蛋白 |
| EP2063905B1 (de) | 2006-09-18 | 2014-07-30 | Raptor Pharmaceutical Inc | Behandlungen von lebererkrankungen durch verabreichung von konjugaten aus rezeptor-assoziierten proteinen |
| JP2010506860A (ja) | 2006-10-19 | 2010-03-04 | アンジオケム，インコーポレーテッド | Ｐ−糖タンパク質機能を刺激するための化合物およびその使用 |
| US9399675B2 (en) | 2007-02-28 | 2016-07-26 | The Board Of Regents Of The University Of Oklahoma | Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration |
| WO2008116171A1 (en) | 2007-03-21 | 2008-09-25 | Raptor Pharmaceutical Inc. | Cyclic receptor-associated protein (rap) peptides |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| AU2008255556B2 (en) | 2007-05-29 | 2014-08-07 | Angiochem, Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| US8802631B2 (en) * | 2007-09-17 | 2014-08-12 | Ludwig Institute For Cancer Research Ltd. | Peptides and methods for the treatment of gliomas and other cancers |
| WO2009046220A2 (en) | 2007-10-02 | 2009-04-09 | Mdrna, Inc. | Lipopeptides for delivery of nucleic acids |
| WO2009070597A2 (en) | 2007-11-26 | 2009-06-04 | Armagen Technologies, Inc. | Fusion proteins for delivery of gdnf to the cns |
| BRPI0821310A2 (pt) | 2007-12-20 | 2015-06-16 | Angiochem Inc | Conjugados polipeptídeos-ácido nucleico e usos dos mesmos |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| JP2011514160A (ja) | 2008-02-21 | 2011-05-06 | バーナム インスティテュート フォー メディカル リサーチ | Ｃ末端エレメントを有するペプチドおよびタンパク質に関する方法および組成物 |
| MX355683B (es) | 2008-04-18 | 2018-04-26 | Angiochem Inc | Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso. |
| US20110117627A1 (en) | 2008-07-10 | 2011-05-19 | The Board Of Trustees Of The University Of Illinois | Regulation of apoptosis by neural specific splice variants of ig20 |
| WO2010043049A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
| CA2740316A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| EP2370472A4 (de) | 2008-12-05 | 2013-04-24 | Angiochem Inc | Leptin- und leptin-analoga-konjugate und ihre verwendungen |
| CA2745524C (en) | 2008-12-05 | 2020-06-09 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| CN102348723A (zh) | 2008-12-05 | 2012-02-08 | 安吉奥开米公司 | 肽治疗剂轭合物及其应用 |
| US8853353B2 (en) | 2008-12-17 | 2014-10-07 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| MX2011011023A (es) | 2009-04-20 | 2012-01-20 | Angiochem Inc | Tratamiento de cancer de ovarios usando un agente anti-cancer conjugado con un analogo de angiopep-2. |
| US20100284921A1 (en) | 2009-05-08 | 2010-11-11 | Temple University - Of The Commonwealth System Of Higher Education | Targeted nanoparticles for intracellular cancer therapy |
| CN102753187A (zh) | 2009-06-03 | 2012-10-24 | 戴瑟纳制药公司 | 肽-dicer底物试剂及其特异性抑制基因表达的方法 |
| CN103819564A (zh) | 2009-06-11 | 2014-05-28 | 安吉奥开米公司 | 用于将gdnf和bdnf递送至中枢神经系统的融合蛋白 |
| RU2012103240A (ru) | 2009-07-02 | 2013-08-10 | Ангиокем Инк. | Мультимерные пептидные конъюгаты и их применение |
| EP3000481A3 (de) | 2009-07-14 | 2016-05-11 | Mayo Foundation for Medical Education and Research | Peptidvermittelte nicht-kovalente verabreichung von wirkstoffen über die blut-hirn-schranke |
| AU2010305284A1 (en) | 2009-10-06 | 2012-05-03 | Angiochem Inc. | Compositions and methods for the transport of therapeutic agents |
| US9095541B2 (en) | 2009-11-24 | 2015-08-04 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
| US8530429B2 (en) | 2009-11-24 | 2013-09-10 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
| EP2333074A1 (de) | 2009-12-14 | 2011-06-15 | Robert Steinfeld | Substanzen und Verfahren zur Behandlung von lyosomalen Speicherkrankheiten |
| AU2011224457B2 (en) | 2010-03-08 | 2014-11-06 | Sloan-Kettering Institute For Cancer Research | Cdc7 kinase inhibitors and uses thereof |
| EP2550285B1 (de) | 2010-03-22 | 2017-07-19 | President and Fellows of Harvard College | Trioxacarcine und deren verwendungen |
| WO2011119608A1 (en) | 2010-03-26 | 2011-09-29 | University Of Tennessee Research Foundation | Peptides that specifically target amyloid deposits |
| CA2796215C (en) | 2010-04-14 | 2021-05-18 | National Research Council Of Canada | Compositions and methods for brain delivery of analgesic peptides |
| WO2011153642A1 (en) | 2010-06-10 | 2011-12-15 | Angiochem Inc. | Leptin and leptin analog conjugates and fusion proteins and uses thereof |
| JP2013530993A (ja) | 2010-07-02 | 2013-08-01 | アンジオケム インコーポレーテッド | 治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用 |
| US8218280B2 (en) | 2010-07-08 | 2012-07-10 | Schneider Electric USA, Inc. | Secondary thermal sensor for primary conductors |
| WO2012018404A2 (en) | 2010-08-06 | 2012-02-09 | U3 Pharma Gmbh | Use of her3 binding agents in prostate treatment |
| CN102406949B (zh) | 2010-09-21 | 2013-05-29 | 复旦大学 | 一种靶向示踪的多模式诊断纳米影像药物 |
| WO2012037687A1 (en) | 2010-09-23 | 2012-03-29 | Angiochem Inc. | Therapeutic polypeptides and uses thereof |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| EP2640359A4 (de) | 2010-11-18 | 2015-11-04 | Gen Hospital Corp | Neue zusammensetzungen und verwendungen blutdrucksenkender mittel zur krebstherapie |
| CN102552928A (zh) | 2010-12-19 | 2012-07-11 | 复旦大学 | 一种治疗脑部肿瘤的双级靶向递药系统及其制备方法 |
| ES2637113T3 (es) | 2011-01-10 | 2017-10-10 | Infinity Pharmaceuticals, Inc. | Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas |
| CN102614105A (zh) | 2011-01-28 | 2012-08-01 | 复旦大学 | 一种脑靶向载两性霉素b聚合物胶束给药系统 |
| EP2680820B1 (de) | 2011-03-01 | 2022-11-02 | 2-BBB Medicines B.V. | Fortschrittliches, aktives liposomales laden von schwer wasserlöslichen substanzen |
| EP2691443B1 (de) | 2011-03-28 | 2021-02-17 | Massachusetts Institute of Technology | Konjugierte lipomers und ihre verwendung |
| WO2012138694A2 (en) | 2011-04-07 | 2012-10-11 | Emory University | Compositions comprising saccharide binding moieties and methods for targeted therapy |
| BR112013028570A2 (pt) | 2011-05-09 | 2019-09-24 | Institut Quim De Sarria | nanopartículas poliméricas para administração de fármacos |
| WO2013004716A1 (en) | 2011-07-04 | 2013-01-10 | Universität Basel | Peptide beads |
| HK1198443A1 (en) | 2011-07-19 | 2015-04-24 | 无限药品股份有限公司 | Heterocyclic compounds and uses thereof |
| AR088218A1 (es) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos utiles como inhibidores de pi3k |
| MY186267A (en) | 2011-08-11 | 2021-07-01 | Intellikine Llc | Kinase inhibitor polymorphs |
| MX2014002542A (es) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| WO2013049332A1 (en) | 2011-09-29 | 2013-04-04 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
| WO2013056096A1 (en) | 2011-10-13 | 2013-04-18 | Angiochem Inc. | Polypeptide-opioid conjugates and uses thereof |
| PE20181541A1 (es) | 2011-10-27 | 2018-09-26 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
| US9403820B2 (en) | 2011-11-11 | 2016-08-02 | Intellikine Llc | Kinase inhibitor polymorphs |
| CN104145015A (zh) | 2011-12-01 | 2014-11-12 | 安吉奥开米公司 | 靶向的溶酶体酶化合物 |
| BR112014013250A2 (pt) | 2011-12-01 | 2019-09-24 | Angiochem Inc | compostos com enzima alvo e usos dos mesmos |
| RU2664698C2 (ru) | 2011-12-13 | 2018-08-21 | Энджинеик Молекьюлар Деливери Пти Лтд | Полученные из бактерий интактные мини-клетки для доставки лекарственных средств к опухолям мозга |
| IN2014DN05912A (de) | 2011-12-16 | 2015-06-05 | Massachusetts Inst Technology | |
| WO2013120107A1 (en) | 2012-02-09 | 2013-08-15 | University Of Rochester | Methods and compositions for treating a subject to inhibit hearing loss |
| EP2819686A4 (de) | 2012-03-02 | 2016-05-25 | Icahn School Med Mount Sinai | Varianten von prothymosin alpha und verfahren zur verwendung davon |
| CN108686203A (zh) | 2012-04-04 | 2018-10-23 | 哈洛齐梅公司 | 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法 |
| EP4005600A1 (de) | 2012-04-26 | 2022-06-01 | Yale University | Gegen hiv gerichtete zytotoxische wirkstoffe freisetzende moleküle (cdm-hs), zytotoxische wirkung gegen das menschliche immunschwächevirus und verfahren zur verwendung |
| AU2013273894A1 (en) | 2012-06-15 | 2015-02-05 | Angiochem Inc. | Targeted iduronidase compounds |
-
2004
- 2004-01-05 WO PCT/CA2004/000011 patent/WO2004060403A2/en not_active Ceased
- 2004-01-05 US US10/541,304 patent/US9221867B2/en active Active
- 2004-01-05 JP JP2006500425A patent/JP4903036B2/ja not_active Expired - Fee Related
- 2004-01-05 AU AU2004203682A patent/AU2004203682B2/en not_active Ceased
- 2004-01-05 EP EP10009847A patent/EP2260874A1/de not_active Withdrawn
- 2004-01-05 ES ES04700102T patent/ES2368941T3/es not_active Expired - Lifetime
- 2004-01-05 MX MXPA05007322A patent/MXPA05007322A/es active IP Right Grant
- 2004-01-05 CN CN2012102486937A patent/CN102775472A/zh active Pending
- 2004-01-05 SI SI200431732T patent/SI1583562T1/sl unknown
- 2004-01-05 BR BR0406647-2A patent/BRPI0406647A/pt not_active Application Discontinuation
- 2004-01-05 EP EP04700102A patent/EP1583562B1/de not_active Expired - Lifetime
- 2004-01-05 CA CA2516056A patent/CA2516056C/en not_active Expired - Lifetime
- 2004-01-05 CN CN2004800035448A patent/CN1747747B/zh not_active Expired - Fee Related
- 2004-01-05 DK DK04700102.9T patent/DK1583562T3/da active
- 2004-01-05 AT AT04700102T patent/ATE512674T1/de active
- 2004-01-05 PT PT04700102T patent/PT1583562E/pt unknown
-
2009
- 2009-12-29 AU AU2009251223A patent/AU2009251223B2/en not_active Ceased
-
2011
- 2011-09-15 CY CY20111100889T patent/CY1111844T1/el unknown
- 2011-10-28 JP JP2011237203A patent/JP2012031197A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN1747747A (zh) | 2006-03-15 |
| CY1111844T1 (el) | 2015-10-07 |
| US20060182684A1 (en) | 2006-08-17 |
| CN102775472A (zh) | 2012-11-14 |
| AU2009251223B2 (en) | 2012-02-09 |
| AU2004203682A1 (en) | 2004-07-22 |
| US9221867B2 (en) | 2015-12-29 |
| EP1583562B1 (de) | 2011-06-15 |
| SI1583562T1 (sl) | 2011-10-28 |
| WO2004060403A3 (en) | 2004-11-18 |
| EP1583562A2 (de) | 2005-10-12 |
| ES2368941T3 (es) | 2011-11-23 |
| CA2516056A1 (en) | 2004-07-22 |
| AU2009251223A1 (en) | 2010-01-28 |
| AU2004203682A8 (en) | 2009-09-17 |
| BRPI0406647A (pt) | 2005-12-06 |
| JP2006515363A (ja) | 2006-05-25 |
| CA2516056C (en) | 2012-05-29 |
| EP2260874A1 (de) | 2010-12-15 |
| DK1583562T3 (da) | 2011-09-19 |
| JP2012031197A (ja) | 2012-02-16 |
| AU2004203682B2 (en) | 2009-10-01 |
| MXPA05007322A (es) | 2006-02-17 |
| JP4903036B2 (ja) | 2012-03-21 |
| WO2004060403A2 (en) | 2004-07-22 |
| PT1583562E (pt) | 2011-09-19 |
| CN1747747B (zh) | 2012-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE512674T1 (de) | Angiopep-1, verwandte verbindungen, und deren verwnedungen | |
| NO20081005L (no) | 8-methoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents | |
| TW200728276A (en) | Oxindole derivatives | |
| SI1767535T1 (sl) | Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh | |
| ATE536163T1 (de) | Verpackung für medizinische produkte und dergleichen | |
| ES2422557T3 (es) | Compuestos y composiciones como moduladores de la ruta Hedgehog | |
| BR0308613A (pt) | Combinação de compostos orgânicos | |
| ATE474591T1 (de) | Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung | |
| CY1112185T1 (el) | Σταθερο συμπλοκο δραστικων ουσιων απο αλατα των o-ακετυλοσαλικυλικων οξεων με βασικα αμινοξεα και γλυκινη | |
| ATE438626T1 (de) | 4,4-difluor-1,2,3,4-tetrahydro-5h-1- benzazepinderivate und deren salze | |
| EP2077111A4 (de) | Antidepressivum | |
| NO20091495L (no) | Pyrazolopyrimidinderivat | |
| DE602004031954D1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| ATE516031T1 (de) | Verbindungen gegen krebs | |
| ATE398122T1 (de) | Dimere verbindungen und deren verwendung als antivirale mittel | |
| ATE444968T1 (de) | Neuroprotektive verbindungen und deren verwendungen | |
| AR048957A1 (es) | Derivados ciclopeptidos dotados de actividad anti-integrina. | |
| ATE344264T1 (de) | Porphyrin-verbindung, deren albumin- einschlussverbindung und künstlicher sauerstoffträger | |
| EP1433480A4 (de) | Pyrimidinderivate enthaltendes medikament | |
| MXPA04006600A (es) | Dihidrotiazina-y dihidrotiopiran-oxazolidinonas antimicrobianas. | |
| TH59377A3 (th) | อนุพันธ์อินโดล | |
| TH88496A (th) | สารประกอบเคมี | |
| TH76783A (th) | สารประกอบชนิดใหม่ | |
| TH78678A (th) | ตัวยับยั้ง c-แอริลกลูโคไซด์ sglt2 และวิธี | |
| TH82744A (th) | รูปแบบหน่วยยา |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1583562 Country of ref document: EP |